Viking Therapeutics Inc (NASDAQ: VKTX) on Friday, soared 5.43% from the previous trading day, before settling in for the closing price of $62.45. Within the past 52 weeks, VKTX’s price has moved between $8.28 and $99.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -9.64%. With a float of $103.66 million, this company’s outstanding shares have now reached $110.80 million.
In an organization with 27 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 32.11%, operating margin of -28595.64%, and the pretax margin is -22189.22%.
Viking Therapeutics Inc (VKTX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Viking Therapeutics Inc is 6.44%, while institutional ownership is 74.43%. The most recent insider transaction that took place on Sep 20 ’24, was worth 715,850. In this transaction Director of this company sold 10,300 shares at a rate of $69.50, taking the stock ownership to the 9,500 shares. Before that another transaction happened on Sep 20 ’24, when Company’s President & CEO sold 216,130 for $70.83, making the entire transaction worth $15,308,553. This insider now owns 2,304,927 shares in total.
Viking Therapeutics Inc (VKTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -9.64% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 40.00% during the next five years compared to -18.89% drop over the previous five years of trading.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Viking Therapeutics Inc (VKTX) is currently performing well based on its current performance indicators. A quick ratio of 37.69 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of Viking Therapeutics Inc (VKTX)
Let’s dig in a bit further. During the last 5-days, its volume was 2.74 million. That was inferior than the volume of 4.39 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 37.59%. Additionally, its Average True Range was 3.80.
During the past 100 days, Viking Therapeutics Inc’s (VKTX) raw stochastic average was set at 75.16%, which indicates a significant increase from 64.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.42% in the past 14 days, which was lower than the 82.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $61.25, while its 200-day Moving Average is $56.16. However, in the short run, Viking Therapeutics Inc’s stock first resistance to watch stands at $67.35. Second resistance stands at $68.86. The third major resistance level sits at $71.30. If the price goes on to break the first support level at $63.40, it is likely to go to the next support level at $60.96. Assuming the price breaks the second support level, the third support level stands at $59.45.
Viking Therapeutics Inc (NASDAQ: VKTX) Key Stats
Market capitalization of the company is 7.30 billion based on 110,268K outstanding shares. Right now, sales total 0 K and income totals -85,900 K. The company made 0 K in profit during its latest quarter, and -22,250 K in sales during its previous quarter.
